Fisher Asset Management LLC decreased its position in First Tracks Biotherapeutics (NASDAQ:TRAX – Free Report) by 48.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,561 shares of the company’s stock after selling 24,988 shares during the quarter. Fisher Asset Management LLC owned approximately 0.06% of First Tracks Biotherapeutics worth $941,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of TRAX. State Street Corp bought a new position in shares of First Tracks Biotherapeutics during the second quarter valued at about $30,439,000. Opaleye Management Inc. bought a new stake in shares of First Tracks Biotherapeutics in the second quarter worth about $1,308,000. Wellington Management Group LLP bought a new stake in shares of First Tracks Biotherapeutics in the second quarter worth about $1,156,000. Tidal Investments LLC bought a new stake in shares of First Tracks Biotherapeutics in the second quarter worth about $622,000. Finally, Corient Private Wealth LP bought a new stake in shares of First Tracks Biotherapeutics in the second quarter worth about $610,000.
Insider Buying and Selling at First Tracks Biotherapeutics
In other news, Director J. Ware sold 39,265 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $44.78, for a total value of $1,758,286.70. Following the sale, the director directly owned 15,660 shares of the company’s stock, valued at $701,254.80. This represents a 71.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Analysts Set New Price Targets
TRAX has been the topic of a number of research analyst reports. Wall Street Zen upgraded First Tracks Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 17th. Weiss Ratings cut First Tracks Biotherapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, November 9th. Piper Sandler increased their price objective on First Tracks Biotherapeutics from $54.00 to $95.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Wolfe Research started coverage on First Tracks Biotherapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $83.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $57.00 target price on shares of First Tracks Biotherapeutics in a research note on Thursday, September 3rd. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $72.17.
View Our Latest Research Report on First Tracks Biotherapeutics
First Tracks Biotherapeutics Stock Up 2.1%
Shares of TRAX stock opened at $44.50 on Thursday. The stock has a market cap of $1.87 billion and a price-to-earnings ratio of -15.95. The business’s fifty day moving average is $40.16 and its 200 day moving average is $32.75. First Tracks Biotherapeutics has a twelve month low of $14.72 and a twelve month high of $54.78.
First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Equities research analysts expect that First Tracks Biotherapeutics will post -4.24 earnings per share for the current fiscal year.
First Tracks Biotherapeutics Profile
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.
Further Reading
- Five stocks we like better than First Tracks Biotherapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
